nature reviews
clinical oncology

Research Highlight | Published: 11 December 2023

Targeted therapy

Tovorafenib effective against low-grade gliomas harbouring *BRAF* fusions

Peter Sidaway

Nature Reviews Clinical Oncology (2023)

The FDA approval of dabrafenib plus trametinib in March 2023 provided a much-needed targeted therapy option for patients with $BRAF^{V600E}$-mutant low-grade glioma (LGG). Nonetheless, as a type I kinase inhibitor, dabrafenib is ineffective in patients with *BRAF* fusions, including *KIAA1549–BRAF*, which

Access options

References

Original article

Kilburn, L. R. et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. *Nat. Med.* https://doi.org/10.1038/s41591-023-02668-y (2023)

Author information

Authors and Affiliations

Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

Peter Sidaway

Corresponding author

Correspondence to Peter Sidaway.

Rights and permissions

About this article

Cite this article

Sidaway, P. Tovorafenib effective against low-grade gliomas harbouring *BRAF* fusions. *Nat Rev Clin Oncol* (2023). https://doi.org/10.1038/s41571-023-00845-z

Published

11 December 2023

DOI

https://doi.org/10.1038/s41571-023-00845-z

Subjects Cancer genetics • CNS cancer • Paediatric cancer • Targeted therapies

Nature Reviews Clinical Oncology (*Nat Rev Clin Oncol*) | ISSN 1759-4782 (online) | ISSN 1759-4774 (print)